oseen · source-linked reporting

Singapore-based Hilleman Laboratories announces plans to advance an rVSV-based vaccine against the Bundibugyo

2026 Ebola epidemic — Singapore-based Hilleman Laboratories announces plans to advance an rVSV-based vaccine against the Bundibugyo strain of Ebola into human trials after World Health Organization expe

Published July 30, 2026· Updated October 28, 2026·1 min read

Image: “Map_of_the_Ituri_Province_Ebola_outbreak.svg.png” via Wikimedia Commons. Images shown are not owned by Orubus, Oseen or any of its related companies — all rights remain with the stated owners and licensors.

Context: 2026 Ebola epidemic.

Singapore-based Hilleman Laboratories announces plans to advance an rVSV-based vaccine against the Bundibugyo strain of Ebola into human trials after World Health Organization experts identified it as the most promising candidate for the epidemic. [https://www.channelnewsasia.com/singapore/singapore-ebola-vaccine-hilleman-laboratories-merck-bundibugyo-6288361 (AFP via CNA)]

Event summary via Wikipedia Current Events (2026-07-30).